ACR Convergence 2025| Video: Rheuminations on Milestones & Ageism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cardiovascular disease

Can Certain DMARDs Treat Dementia?

Larry Beresford  |  April 26, 2018

In the complex web of interactions between systemic inflammatory response, rheumatic disease and disease-modifying anti-rheumatic drugs (DMARDs), what is the potential for using rheumatologic therapies to treat other medical conditions linked to inflammation? Some medical researchers have looked at cardiac conditions, and others have examined the overlap with Alzheimer’s disease and other dementias. Positive effects…

Filed under:Uncategorized Tagged with:Alzheimer's DiseasedementiaDisease-modifying antirheumatic drugs (DMARDs)

Anton Khrupin / Shutterstock.com

Case Report: Cardiac Complications in Scleroderma

Sophia C. Weinmann, MD, & Richard D. Brasington Jr., MD, FACP  |  April 26, 2018

A 58-year-old African American woman with a past medical history of hypertension (HTN), hyperlipidemia, severe gastroesophageal reflux disease (GERD) and limited cutaneous systemic sclerosis (lcSSc) presented to the emergency department with shortness of breath (SOB) and progressive bilateral lower extremity swelling for three weeks. She denied any chest pain, but endorsed generalized fatigue and dyspnea…

Filed under:Systemic Sclerosis Tagged with:arrhythmiacase reportpulmonary fibrosisScleroderma

Poor Sleep Quality During Menopause Tied to Increased Inflammation

Cheryl Platzman Weinstock  |  April 17, 2018

(Reuters Health)—Middle-aged women who get poor quality sleep have elevated levels of inflammatory markers, suggesting their risk for heart disease and other illnesses may be increased, U.S. researchers say. Based on sleep monitoring and blood tests of 295 women, most of whom were past menopause, researchers found those who had trouble falling asleep or who…

Filed under:Conditions Tagged with:Heart DiseasepostmenopausalpostmenopauseSleepsleep apneaWomen

Tai Chi at Least as Good as Aerobic Exercise for Fibromyalgia

Anne Harding  |  March 31, 2018

NEW YORK (Reuters Health)—Tai chi improves fibromyalgia symptoms at least as effectively as aerobic exercise, according to a new trial. Aerobic exercise is the most commonly recommended non-drug treatment for fibromyalgia, Dr. Chenchen Wang of Tufts University School of Medicine in Boston and her colleagues note in The BMJ, online March 12.1 However, Dr. Wang…

Filed under:ConditionsPain Syndromes Tagged with:Chronic painExerciseExercise/physical therapyFibromyalgiatai chi

Case Report: Metoprolol-Induced Arthralgia

Case Report: Metoprolol-Induced Arthralgia

Saba Ziaee, MD, & Zineb Aouhab, MD  |  March 17, 2018

Various drugs are known to cause musculoskeletal symptoms, such as arthralgias, myalgias, drug-induced lupus and serum sickness.1 In the rheumatology world, the most commonly recognized drugs that can cause musculoskeletal symptoms are hydralazine, minocycline, fluoroquinolones and, recently, the dipeptidyl peptidase 4 (DPP-4) inhibitor class of medications. Although beta blockers also have a noted side effect…

Filed under:ConditionsSoft Tissue Pain Tagged with:arthralgiasbeta blockersmetoprolol

FDA Update: Possible Heart Risks with Clarithromycin; Apadaz Receives FDA Approval

Michele B. Kaufman, PharmD, BCGP  |  March 7, 2018

After reviewing a 10-year study, the FDA cautions that prescribing clarithromycin to patients with heart disease increases the risk of heart problems or death…

Filed under:Drug Updates Tagged with:acute painantibioticsApadazclarithromycinHeart Disease

Inside Cambodia’s Struggles with Poverty, Dearth of Trained Rheumatologists

Elizabeth Hofheinz, MPH, Med  |  December 18, 2017

It’s one thing for a developing country to lack physicians due to a scarcity of training. It’s quite another for such a vacuum to exist because the physicians were executed. In Cambodia in the 1970s, genocide perpetrated by the Khmer Rouge spared few of the educated class. If they were spared, chances were they lost…

Filed under:ConditionsProfiles Tagged with:CambodiacostsDiagnosisDr. Victoria SeligmandrugEducationgenocideHealth Volunteers OverseasKhmer RougeLupuspatient carephysicianpovertyrheumatologistrheumatologySihanouk Hospital Center of HopeSLETrainingVolunteer

Upadacitinib Promising for RA in Phase 3 Study

Michele B. Kaufman, PharmD, BCGP  |  December 5, 2017

In a recent study, upadacitinib proved safe and effective to treat rheumatoid arthritis in patients with inadequate responses to conventional synthetic DMARDs…

Filed under:Biologics/DMARDsDrug Updates Tagged with:Rheumatoid Arthritis (RA)upadacitinib

European Commission Approves Subcutaneous Belimumab for SLE; FDA Safety Alert for Febuxostat

Michele B. Kaufman, PharmD, BCGP  |  November 29, 2017

Subcutaneous belimumab has been approved in the EU to help treat patients with active autoantibody-positive SLE…

Filed under:ConditionsDrug UpdatesGout and Crystalline Arthritis Tagged with:belimumabcardiovascularEuropean UnionFebuxostatGoutInternationalsystemic lupus erythematosus (SLE)

futuristman / shutterstock.com

Fulbright Scholar Researches Physical Activity in Swedish Children with Juvenile Idiopathic Arthritis

Carina Stanton  |  October 18, 2017

A stroll through downtown Stockholm presents a quintessential picture of an active community, with most people biking or walking as their preferred mode of travel. Yet children in Sweden who live with juvenile idiopathic arthritis (JIA)—currently estimated at around 64 of every 100,000—don’t always engage in this active lifestyle.1 Maura Daly Iversen, PT, DPT, SD,…

Filed under:ConditionsPediatric ConditionsProfilesResearch Rheum Tagged with:Dr. Maura IversonFulbright ScholarshipJIAJuvenile idiopathic arthritispatient carePediatricphysical activityResearchrheumatologySweden

  • « Previous Page
  • 1
  • …
  • 50
  • 51
  • 52
  • 53
  • 54
  • …
  • 65
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences